Welshman Richard Twomey joined the company in February of 2014, taking over the role of CEO on 1 April. He was previously International Vice President of the California-based orthodontics company Align Technology and has also held a number of senior positions within divisions of Johnson & Johnson and as President of DePuy, International Ltd.
Martin Lexa is a German national, who before he joined the company held a position as Head HR EMEA at Alcon, a Novartis company. Martin has extensive and broad-based experience in mature and emerging markets for Novartis, Medtronic, Bristol-Myers Squibb and others.
Stefan is a Swedish national and joined the company and the Executive leadership team in December 2016. With a solid background in finance, and a decade within the med-tech industry, he has held senior positions at Getinge and the listed environmental technology group Nederman. Over the years he has gained a broad international experience through assignments in the US, Germany and Switzerland.
Eric has been with the company since 2002 and has held roles as GM of our factory in Waremme, Belgium, as well as heading up various business units within our commercial organisation. Before taking on his current role, he was President of the Surgical Division.
Jakob Hedén is a Swedish national with a solid background in international corporate law, specialising in intellectual property rights and mergers and acquisitions. Prior to joining Mölnlycke Health Care in 2008, Jakob worked for Vinge and Setterwalls, two of the largest law firms in Sweden. During his time at Mölnlycke Health Care, Jakob has held the General Counsel EMEA APAC role and Global Trademark Portfolio responsibility. Since 2014 Jakob has been leading the Global Patent Department and as of February 2016 he is a member of the Executive Leadership team.
Staffan joined Mölnlycke Health Care in March, 2014, and is responsible for our commercial activities, including sales and marketing. Staffan has many years of medical device experience, including working for Johnson & Johnson, where he held various roles across a number of functions and regions, including Regional Vice President for Emerging Markets, based in Brussels.
Barry joined the company in November 2014, after many years' experience in senior roles in healthcare companies around the world – including 20 years at Teleflex, most recently as Chief Technology Officer with global responsibility for Research and Development. He has also acted as Industrial Mentor to the School of Pharmacy at Queens University, Belfast, and was Executive Director, International at Invest, Northern Ireland.
Our Board has seven directors – Gunnar Brock, Fred Cohen, Christer Eriksson, John Hepburn, Clare Hollingworth, Johan Malmqvist and our CEO Richard Twomey – plus one member from Investor AB, Lennart Johansson. Five are independent members. Chairman of the Board Gunnar Brock (one of the five independent Board members) is also from Investor.
Investor AB is a leading owner of Nordic-based international companies, founded by the Wallenberg family in 1916.